Physician profile
Bo Shen
NPI 1497712814
$20,329.14
in general payments reported to CMS, 2019-2025
18 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,203 · 2020: $4,583 · 2021: $1,401 · 2022: $547 · 2023: $364 · 2024: $5,834 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,100 · Food and Beverage: $1,345 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,100.00 |
| Food and Beverage | $1,345.08 |
| Education | $149.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $9,785.18 | 2020-2025 | Tremfya, Stelara |
| Abbvie INC. | $8,142.55 | 2019-2025 | Skyrizi, Rinvoq |
| Inova Diagnostics, INC. | $750.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $378.47 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.85 | 2021-2024 | Xifaxan |
| Boston Scientific Corporation | $200.72 | 2019-2023 | Spyglass |
| Covidien LP | $156.72 | 2019 | |
| Daiichi Sankyo INC. | $144.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $108.23 | 2021-2024 | Dificid |
| Celgene Corporation | $100.88 | 2021-2024 | Zeposia |
| Organon LLC | $88.67 | 2021 | |
| Redhill Biopharma INC. | $74.31 | 2021 | |
| Celltrion USA INC. | $59.64 | 2023 | Yuflyma |
| Pfizer INC. | $57.32 | 2021 | |
| Mallinckrodt Hospital Products INC. | $36.46 | 2025 | Terlivaz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $31.63 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bo Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.